Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease

We report 3 patients with coronavirus disease who had a decline in respiratory status during their hospital course that responded well to intravenous steroids and interleukin-6 receptor antagonist therapy. These patients later showed development of persistent hypoxia with increased levels of d-dimer levels and were given a diagnosis of pulmonary embolisms

Comment in: Emerg Infect Dis. 2020 Oct;26(10):2522-2533. - PMID 32614766
Year of Publication: 2020
Contained in: Emerging infectious diseases Vol. 26, No. 8 (2020), p. 1941-1943
All journal articles: Search for all articles in this journal
Language: English
Contributors: Griffin, Daniel O | Author
Jensen, Alexandra
Khan, Mushmoom
Chin, Jessica
Chin, Kelly
Saad, Jennifer
Parnell, Ryan
Awwad, Christopher
Patel, Darshan
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 5GMR90S4KN
9NDF7JZ4M3
COVID-19
Case Reports
I031V2H011
Journal Article
SARS-CoV-2
coronavirus disease
d-dimer
deep vein thrombosis
fibrin fragment D
hypercoagulability
prophylaxis
pulmonary embolism
respiratory infections
sequelae
severe acute respiratory syndrome coronavirus 2
thromboembolic
tocilizumab
viruses
Additional Keywords: Acute Disease
Aged
Antibodies, Monoclonal, Humanized
Anticoagulants
Betacoronavirus
Biomarkers
Clinical Laboratory Techniques
Coronavirus Infections
Cytokine Release Syndrome
Enoxaparin
Female
Fibrin Fibrinogen Degradation Products
Humans
Hypoxia
Male
Methylprednisolone Hemisuccinate
Middle Aged
Pandemics
Pneumonia, Viral
Pulmonary Embolism
Rivaroxaban
Tomography, X-Ray Computed
Treatment Outcome
ISSN: 1080-6059
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 29.07.2020
Date Revised 25.09.2020
published: Print-Electronic
CommentIn: Emerg Infect Dis. 2020 Oct;26(10):2522-2533. - PMID 32614766
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32348233
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.3201/eid2608.201477
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 05505nma a2201381 c 4500
001 NLM310180473
003 DE-601
005 20200925213821.0
007 cr uuu---uuuuu
008 200430s2020 000 0 eng d
024 7 |a 10.3201/eid2608.201477  |2 doi 
028 5 2 |a pubmed20n1351.xml 
035 |a (DE-599)NLM32348233 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Griffin, Daniel O 
245 1 0 |a Pulmonary Embolism and Increased Levels of d-Dimer in Patients with Coronavirus Disease  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 29.07.2020 
500 |a Date Revised 25.09.2020 
500 |a published: Print-Electronic 
500 |a CommentIn: Emerg Infect Dis. 2020 Oct;26(10):2522-2533. - PMID 32614766 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a We report 3 patients with coronavirus disease who had a decline in respiratory status during their hospital course that responded well to intravenous steroids and interleukin-6 receptor antagonist therapy. These patients later showed development of persistent hypoxia with increased levels of d-dimer levels and were given a diagnosis of pulmonary embolisms 
611 2 7 |a Case Reports  |2 gnd 
611 2 7 |a Journal Article  |2 gnd 
653 2 |a Acute Disease  |6 D000208 
653 2 |a Aged  |6 D000368 
653 2 |a Antibodies, Monoclonal, Humanized  |6 D061067  |a therapeutic use  |6 Q000627 
653 2 |a Anticoagulants  |6 D000925  |a therapeutic use  |6 Q000627 
653 2 |a Betacoronavirus  |6 D000073640  |a drug effects  |6 Q000187  |a *pathogenicity  |6 Q000472  |a physiology  |6 Q000502 
653 2 |a Biomarkers  |6 D015415  |a blood  |6 Q000097 
653 2 |a Clinical Laboratory Techniques  |6 D019411  |a methods  |6 Q000379 
653 2 |a Coronavirus Infections  |6 D018352  |a *complications  |6 Q000150  |a diagnosis  |6 Q000175  |a drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Cytokine Release Syndrome  |6 D000080424  |a *complications  |6 Q000150  |a diagnosis  |6 Q000175  |a drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Enoxaparin  |6 D017984  |a therapeutic use  |6 Q000627 
653 2 |a Female  |6 D005260 
653 2 |a Fibrin Fibrinogen Degradation Products  |6 D005338  |a *metabolism  |6 Q000378 
653 2 |a Humans  |6 D006801 
653 2 |a Hypoxia  |6 D000860  |a *complications  |6 Q000150  |a diagnosis  |6 Q000175  |a drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Male  |6 D008297 
653 2 |a Methylprednisolone Hemisuccinate  |6 D008776  |a therapeutic use  |6 Q000627 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a *complications  |6 Q000150  |a diagnosis  |6 Q000175  |a drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Pulmonary Embolism  |6 D011655  |a *complications  |6 Q000150  |a diagnosis  |6 Q000175  |a drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Rivaroxaban  |6 D000069552  |a therapeutic use  |6 Q000627 
653 2 |a Tomography, X-Ray Computed  |6 D014057 
653 2 |a Treatment Outcome  |6 D016896 
655 7 |a COVID-19  |2 gnd 
655 7 |a SARS-CoV-2  |2 gnd 
655 7 |a coronavirus disease  |2 gnd 
655 7 |a d-dimer  |2 gnd 
655 7 |a deep vein thrombosis  |2 gnd 
655 7 |a hypercoagulability  |2 gnd 
655 7 |a prophylaxis  |2 gnd 
655 7 |a pulmonary embolism  |2 gnd 
655 7 |a respiratory infections  |2 gnd 
655 7 |a sequelae  |2 gnd 
655 7 |a severe acute respiratory syndrome coronavirus 2  |2 gnd 
655 7 |a thromboembolic  |2 gnd 
655 7 |a viruses  |2 gnd 
655 7 |a Antibodies, Monoclonal, Humanized  |2 gnd 
655 7 |a Anticoagulants  |2 gnd 
655 7 |a Biomarkers  |2 gnd 
655 7 |a Enoxaparin  |2 gnd 
655 7 |a Fibrin Fibrinogen Degradation Products  |2 gnd 
655 7 |a fibrin fragment D  |2 gnd 
655 7 |a Methylprednisolone Hemisuccinate  |2 gnd 
655 7 |a 5GMR90S4KN  |2 gnd 
655 7 |a Rivaroxaban  |2 gnd 
655 7 |a 9NDF7JZ4M3  |2 gnd 
655 7 |a tocilizumab  |2 gnd 
655 7 |a I031V2H011  |2 gnd 
689 0 0 |A f  |a Case Reports 
689 0 1 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a SARS-CoV-2 
689 1 2 |a coronavirus disease 
689 1 3 |a d-dimer 
689 1 4 |a deep vein thrombosis 
689 1 5 |a hypercoagulability 
689 1 6 |a prophylaxis 
689 1 7 |a pulmonary embolism 
689 1 8 |a respiratory infections 
689 1 9 |a sequelae 
689 1 X |a severe acute respiratory syndrome coronavirus 2 
689 1 X |a thromboembolic 
689 1 X |a viruses 
689 1 |5 DE-601 
689 2 0 |a Antibodies, Monoclonal, Humanized 
689 2 1 |a Anticoagulants 
689 2 2 |a Biomarkers 
689 2 3 |a Enoxaparin 
689 2 4 |a Fibrin Fibrinogen Degradation Products 
689 2 5 |a fibrin fragment D 
689 2 6 |a Methylprednisolone Hemisuccinate 
689 2 7 |A r  |a 5GMR90S4KN 
689 2 8 |a Rivaroxaban 
689 2 9 |A r  |a 9NDF7JZ4M3 
689 2 X |a tocilizumab 
689 2 X |A r  |a I031V2H011 
689 2 |5 DE-601 
700 1 |a Jensen, Alexandra 
700 1 |a Khan, Mushmoom 
700 1 |a Chin, Jessica 
700 1 |a Chin, Kelly 
700 1 |a Saad, Jennifer 
700 1 |a Parnell, Ryan 
700 1 |a Awwad, Christopher 
700 1 |a Patel, Darshan 
773 0 8 |i in  |t Emerging infectious diseases  |g Vol. 26, No. 8 (2020), p. 1941-1943  |q 26:8<1941-1943  |w (DE-601)NLM088706532  |x 1080-6059 
856 4 1 |u http://dx.doi.org/10.3201/eid2608.201477  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 26  |j 2020  |e 8  |b 02  |c 08  |h 1941-1943